EPIX
Closed
Essa Pharma Inc
1.73
+0.03 (+1.76%)
Last Update: 01 Jul 2025 23:00:00
Yesterday: 1.7
Day's Range: 1.7 - 1.75
Send
sign up or login to leave a comment!
When Written:
2.97
ESSA Pharma Inc. is a clinical-stage pharmaceutical company based in Vancouver, Canada. The company is focused on developing novel therapies for the treatment of prostate cancer, a disease that affects millions of men worldwide. ESSA Pharma's lead drug candidate, EPI-7386, is a small molecule inhibitor of the androgen receptor (AR), a protein that plays a key role in the growth and progression of prostate cancer. EPI-7386 has shown promising results in preclinical studies and is currently being evaluated in a Phase 1/2 clinical trial in patients with metastatic castration-resistant prostate cancer (mCRPC). ESSA Pharma is also exploring other AR inhibitors and combination therapies for the treatment of prostate cancer. The company was founded in 2009 and became a publicly traded company in 2017.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
sign up or login to leave a comment!!








